Biofrontera AG

Biofrontera AG is a biopharmaceutical company specializing in the development of drugs for the treatment of dermatological and inflammatory diseases. The Company has three product candidates in clinical development for four different clinical indications. The most advanced products are BF-200 ALA (Phase IIb/III) for actinic keratosis and condyloma; and BF-derm 1 (Phase II) for chronic, antihistamine-refractory urticaria. Clinical and preclinical trials have demonstrated the efficacy and excellent safety profile of both products. The third clinical candidate, BF-37, currently enters phase II development for atopic dermatitis.

Contact Details: Hemmelrather Weg 201 Leverkusen 51377 Germany Tel: 49 (0)214-87632-22 Fax: 49 (0)214-87632-90 Email: press@biofrontera.com WWW: www.biofrontera.de/

BioNews Results for Biofrontera AG:
Biofrontera AG (DE) - Ad hoc: Biofrontera AG Placed a Capital Increase	Pharma Live:  Aug 5 2008 3:56PM Matching: biofrontera ag

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 147 times since April 2007, the link to the organisation's website has been followed 30 times

Search for more companies in Leverkusen

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Biofrontera AG